UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alexander Galagan: Russian titan of the enlightenment in the history of accounting

Accounting history, 2019-05, Vol.24 (2), p.293-316

2019

Volltextzugriff (PDF)

Risk of Pneumonitis in Breast Cancer Patients Treated With Radiation Therapy and Combination Chemotherapy With Paclitaxel

JNCI : Journal of the National Cancer Institute, 2001-12, Vol.93 (23), p.1806-1811

2001

Volltextzugriff (PDF)

PMD6 Extracorporeal Photopheresis for the Treatment of Patients With Acute or Chronic Graft Versus Host Disease (GvHD), Refractory to Corticosteroids – A Sytematic Review

Value in health, 2012-11, Vol.15 (7), p.A345-A346

2012

Volltextzugriff (PDF)

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Volltextzugriff (PDF)

0185 High-dose fulvestrant (500 mg): Clinical evidence supporting potentially improved efficacy benefits in hormone receptor-positive (HR+) advanced breast cancer (ABC)

Breast (Edinburgh), 2009, Vol.18, p.S65-S65

2009

Volltextzugriff (PDF)

Breast Cancer Update

The oncologist, 2000, Vol.5 (4), p.285-292

Kuter, Irene

2000

Volltextzugriff (PDF)

A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.S44

2022

Volltextzugriff (PDF)

Impact of Interstitial Fluid Pressure, Tumor Oxygenation, and Chemotherapy Drug Sequencing on Response to Neoadjuvant Chemotherapy and on Long-Term Local Control in Women Treated for Locally Advanced Breast Cancer

International journal of radiation oncology, biology, physics, 2007-11, Vol.69 (3), p.S61-S62

2007

Volltextzugriff (PDF)

Breast Cancer Highlights

The oncologist, 1999, Vol.4 (4), p.299-308

Kuter, Irene

1999

Volltextzugriff (PDF)

358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer

Annals of oncology, 2020-09, Vol.31, p.S394-S394

2020

Volltextzugriff (PDF)

Alexander Galagan: Russian titan of the enlightenment in the history of accounting

Accounting history, 2019-05, Vol.24 (2), p.293-316

2019

Volltextzugriff (PDF)

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

The New England journal of medicine, 2022-04, Vol.386 (15), p.1432-1442

2022

Volltextzugriff (PDF)

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.485-493

1999

Volltextzugriff (PDF)

20 Impact of fulvestrant 500 mg/month versus fulvestrant 250 mg/month on bone turnover markers and endometrial thickness: findings from the NEWEST study

European journal of cancer supplements, 2010, Vol.8 (3), p.64-64

2010

Volltextzugriff (PDF)

Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2722-2730

2001

Volltextzugriff (PDF)

5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.284-285

2009

Volltextzugriff (PDF)

NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer

European journal of cancer supplements, 2008, Vol.6 (7), p.115-115

2008

Volltextzugriff (PDF)

Comparison of the Transcriptional Response to Fulvestrant and Oestrogen Deprivation in ER-Positive Breast Cancer in Vitro and in Vivo

Annals of oncology, 2013-05, Vol.24, p.iii46

2013

Volltextzugriff (PDF)

Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.579-579

2008

Volltextzugriff (PDF)

New Thrombopoietic Agents: Introduction

Seminars in hematology, 2010-07, Vol.47 (3), p.211-211

2010

Volltextzugriff (PDF)

Breast cancer

The oncologist (Dayton, Ohio), 2001, Vol.6 (4), p.338

Kuter, I

2001

Volltextzugriff (PDF)

Breast cancer

The oncologist (Dayton, Ohio), 2001-01, Vol.6 (4), p.338-346

Kuter, I

2001

Volltextzugriff (PDF)

Abstract P1-12-02: Transcriptional Changes Induced by Anastrozole and Fulvestrant Treatment in ER-Positive Breast Cancers

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P1-P1-12-02

2010

Volltextzugriff (PDF)

Comparison of Methods for Detection of Fulvestrant-Induced Changes in Breast Tumor Estrogen and Progesterone Receptor Expression in a Neoadjuvant Trial (NEWEST)

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.1087-1087

2009

Volltextzugriff (PDF)

Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11602-e11602

2009

Volltextzugriff (PDF)

1 – 25 von 1.144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(968)
Mit Volltextzugriff
(916)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(124)
Ethnomusicology
(29)
Vaccine
(29)
The New England Journal Of Medicine
(25)
British Journal Of Haematology
(24)
American Journal Of Hematology
(23)
The Pediatric Infectious Disease Journal
(23)
Pharmacological Reports
(20)
Transfusion
(15)
Hemasphere
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Alexander Galagan: Russian titan of the enlightenment in the history of accounting

Risk of Pneumonitis in Breast Cancer Patients Treated With Radiation Therapy and Combination Chemotherapy With Paclitaxel

PMD6 Extracorporeal Photopheresis for the Treatment of Patients With Acute or Chronic Graft Versus Host Disease (GvHD), Refractory to Corticosteroids – A Sytematic Review

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

0185 High-dose fulvestrant (500 mg): Clinical evidence supporting potentially improved efficacy benefits in hormone receptor-positive (HR+) advanced breast cancer (ABC)

Breast Cancer Update

A Phase I Study of Adjuvant Niraparib Administered Concurrently with Postoperative Radiation Therapy in Patients with Localized Triple Negative Breast Cancer

Impact of Interstitial Fluid Pressure, Tumor Oxygenation, and Chemotherapy Drug Sequencing on Response to Neoadjuvant Chemotherapy and on Long-Term Local Control in Women Treated for Locally Advanced Breast Cancer

Breast Cancer Highlights

358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer

Alexander Galagan: Russian titan of the enlightenment in the history of accounting

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

20 Impact of fulvestrant 500 mg/month versus fulvestrant 250 mg/month on bone turnover markers and endometrial thickness: findings from the NEWEST study

Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer

NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer

Comparison of the Transcriptional Response to Fulvestrant and Oestrogen Deprivation in ER-Positive Breast Cancer in Vitro and in Vivo

Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST study

New Thrombopoietic Agents: Introduction

Breast cancer

Breast cancer

Abstract P1-12-02: Transcriptional Changes Induced by Anastrozole and Fulvestrant Treatment in ER-Positive Breast Cancers

Comparison of Methods for Detection of Fulvestrant-Induced Changes in Breast Tumor Estrogen and Progesterone Receptor Expression in a Neoadjuvant Trial (NEWEST)

Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST)

Suchergebnisse filtern